Neovascular AMD

Macular Disease Foundation Australia (MDFA) is calling on the next Federal Government to allow bulk billing of eye injections for...

The Federal Government is implementing a controversial recommendation from the taskforce review into ophthalmology Medicare items that will mean macular...

Macular Disease Foundation Australia (MDFA) has launched Eye Connect, a comprehensive support service for people living with macular disease and...

A landmark trial has successfully used a radiotherapy robot system to treat neovascular age-related macular degeneration (nAMD). In the study...

The Australian Therapeutic Goods Administration (TGA) has approved Eylea 8mg, a higher dose of aflibercept for adults with neovascular aged-related...

Optometrists have an opportunity to maximise care for their patients after they depart the consulting room thanks to patient support...

People often turn to supplements or superfoods to ward off macular disease or prevent its progression, but new Australian nutritional...

The Australian eyecare sector is challenging the idea that vision loss with age is inevitable. This, combined with cutting-edge research...

A single-dose gene therapy for neovascular age-related macular degeneration (nAMD) is now in Phase 3 clinical trials and, if approved,...

A UNSW-developed molecule that could be administered via an eye drop for neovascular age-related macular degeneration (nAMD) is being commercialised...